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Background: Metastasis to the cervical (neck) lymph nodes is one of the most significant clinical factors
responsible for death from oral squamous cell carcinoma (SCC). Therefore, the lymph nodes are frequently removed
when the tumor is excised (neck dissection), even though the majority of patients will not benefit from the extra
surgery. Two subtypes of oral SCC distinguished by the presence of tumor genomic aberrations +3q, −8p, +8q
and/or +20 differ in risk for metastasis – high for the 3q8pq20 subtype, harboring one or more of the aberrations
and low for the non-3q8pq20 subtype, lacking these alterations. A prior analysis of the literature suggested genes
differentially methylated in the two subtypes. Therefore, the goal of this study was to further investigate the
methylation status of candidate biomarkers of the non-3q8pq20 subtype, and evaluate their utility for identifying
patients at low risk for metastasis.
Methods: Methylation status of genes in a cohort of 52 oral SCC patients with at least five year follow up was
determined by pyrosequencing. Gene expression levels were determined by quantitative RT-PCR. Growth following
re-expression of HOXA9 in cultured oral SCC cells was assessed by proliferation and colony formation assays.
Results: A pilot study evaluating methylation levels of HOXA9, MT1A and HOXA11 promoters in DNA from 12
tumors (six each of the 3q8pq20 and non-3q8pq20 subtypes) revealed that only HOXA9 was differentially methylated.
Significant differences in methylation levels of HOXA9 were observed amongst the 52 oral SCCs with respect to
genomic subtype and nodal status (p = 0.014, and p = 0.024, respectively, Wilcoxon rank sum test). High levels of HOXA9
methylation and low levels of expression in oral SCC cell lines were observed compared to HaCaT, a non-tumorigenic
keratinocyte cell line. Re-expression of HOXA9 in the SCC4 oral cancer cell line resulted in diminished proliferation and
colony formation.
Conclusions: HOXA9 methylation is frequent in oral cancers and levels are higher in tumors with greater risk of
metastasis. Expression of HOXA9 is low in cells with high levels of methylation and reduced expression appears to
confer a growth advantage.
Keywords: Oral cancer, Metastasis, HOXA9, Methylation, Pyrosequencing* Correspondence: da66@nyu.edu
1Helen Diller Family Comprehensive Cancer Center, University of California
San Francisco, 1450 Third Street, San Francisco, CA 94158-9001, USA
2Bluestone Center for Clinical Research, New York University College of
Dentistry, 421 First Avenue, New York, NY 10010-4086, USA
Full list of author information is available at the end of the article
© 2014 Uchida et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Uchida et al. BMC Cancer 2014, 14:353 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/353Background
Metastasis to the cervical (neck) lymph nodes is one of
the most significant clinical factors responsible for death
from oral squamous cell carcinoma (SCC). Currently,
there are no satisfactory clinical, imaging, pathologic
or molecular techniques that can reliably determine if
neck metastases are present at the time of surgery to
remove the primary tumor. Therefore, patients and phy-
sicians frequently elect to remove the cervical lymph
nodes (neck dissection) at the time the tumor is excised
if the chance of metastasis is > 20% based on current
imperfect risk assessment capability. This surgical pro-
cedure is lengthy, complex, and risky with high mor-
bidity due to functional deficits and disfigurement.
Being able to determine which patients do not need
such surgery would have a substantial, immediate clinical
benefit.
We recently reported that two subtypes of oral SCC
distinguished by tumor genomic aberrations differ in
risk for metastasis [1]. One subtype, the 3q8pq20 sub-
type, is characterized by the presence of one or more
of the recurrent copy number aberrations, +3q, −8p, +8q
and/or +20 and has a substantial risk of metastasis
(46%). The other subtype (non-3q8pq20) lacks these
copy number alterations and is associated with a low
risk of metastasis (7%). These initial studies, which were
replicated in a small independent cohort, indicated
that non-3q8pq20 status has 93% negative predictive
value (NPV), i.e., ability to predict that these cases do
not have neck metastases, and thus do not need neck
dissection.
The non-3q8pq20 tumors lack chromosome level in-
stability, which suggests that development of these tu-
mors could be associated with other, copy number
neutral, mechanisms, such as microsatellite instability or
epigenetic alterations. Microsatellite instability is not
common in oral SCC from western countries, whereas
genome-wide alterations in methylation patterns are ob-
served [2,3]. Analysis of a head and neck cancer patient
cohort [2] for which both copy number and methylation
measurements were available (NCBI GEO accession
numbers GSE20939 and GSE20742, respectively) found
15 loci significantly differentially methylated in 3q8pq20
compared to non-3q8pq20 tumors and normal oral tis-
sue [1]. To investigate whether these loci are a potential
biomarker for distinguishing 3q8pq20 and non-3q8pq20
tumors, we investigated the methylation status of the
loci in an oral SCC cohort in which 3q8pq20 status had
been determined [1]. The overall goal was to develop a
simple assay for 3q8pq20 status utilizing a panel of dif-
ferentially methylated loci that could be performed on
tissue samples obtained by a non-invasive technique
prior to surgery and thus guide decisions regarding the
need for neck dissection.Methods
Patients and tissue samples
The study was approved by the Institutional Review
Board of the University of California San Francisco
(H7867-23910-05). Formalin fixed paraffin embedded
(FFPE) SCC surgical resection specimens were available
from 52 cases of the previously published SCC cohort#2
[1] and included oral cavity sites–tongue, gingiva, floor of
mouth, retromolar trigone and buccal mucosa. Associated
clinical data were obtained through the University of
California San Francisco Oral Cancer Tissue Bank and
Cancer Registry (Table 1 and Additional file 1: Table S1
of reference [1]). Patient consent was obtained for use of
all specimens.
Tumor cell lines
Human oral tongue SCC cell lines SCC4, SCC9, SCC15
and SCC25 were obtained from the American Type
Culture Collection (Manassas, VA), BICR16, H357, H103,
PE/CA-PJ15, and PE/CA-PJ49 from the Health Protection
Agency Culture Collections (HPA, Salisbury, UK), CAL33
from Deutsche Sammlung von Mikroorganismen und
Zellculturen GmbH (DSMZ, Braunschweig, Germany),
and OSC20 from the Japanese Collection of Research
Biosources (Osaka, Japan). The DOK cell line, derived
from a human oral dysplasia was obtained from the
Health Protection Agency Culture Collections (HPA,
Salisbury, UK) and HaCaT, a skin keratinocyte line was
from the Deutsche Sammlung von Mikroorganismen und
Zellculturen GmbH (DSMZ, Braunschweig, Germany).
Cells were propagated according to the methods recom-
mended by the suppliers.
Bisulfite conversion and pyrosequencing
The DNA concentration was quantified by Quant-iT™
dsDNA BR Assay (Life Technologies, Grand Island, NY).
A total of 200 ng of each DNA sample was bisulfite con-
verted with the EZ DNA Methylation-Direct Kit (Zymo Re-
search, Orange, CA). EpiTect Control DNA (QIAGEN,
Germantown, MD) was used as methylated and unmethy-
lated control DNA. PyroMark assays (QIAGEN, German-
town, MD) were used to determine methylation status of
HOXA9 (Hs_HOXA9_05_PM) and MT1A (HS_MT1A_




fite PCR was performed using the PyroMark PCR kit
(QIAGEN, Germantown, MD) and amplification was car-
ried out by an initial incubation at 95°C for 15 min,
followed by 45 cycles of 94°C for 30 sec, 55°C for 30 sec,
72°C for 30 sec. A final incubation was carried out at 72°C
for 10 min. The biotinylated PCR product was purified
and subjected to pyrosequencing using the PyroMark Q24




AB003 Retromolar Region N0 Yes
AB004 Gingiva N0 Yes
AB007 Floor of Mouth N+ Yes
AB010 Tongue N0 Yes
AB011 Tongue N0 Yes
AB014 Retromolar Region N+ Yes
AB015 Tongue N+ Yes
AB017 Buccal Mucosa N+ Yes
AB018 Floor of Mouth N+ Yes
AB019 Floor of Mouth, tongue N+ Yes
AB020 Hard Palate N+ Yes
AB021 Tongue N0 no
AB023 Tongue N0 Yes
AB025 Gingiva N0 No
AB026 Retromolar Region N0 Yes
AB029 Floor of Mouth, tongue, buccal mucosa N0 Yes
AB031 Tongue N0 Yes
AB032 Buccal Mucosa N0 Yes
AB033 Retromolar Region N+ Yes
AB034 Buccal Mucosa N0 No
AB035 Tongue N0 No
AB039 Gingiva N0 Yes
AB041 Tongue N0 Yes
AB042 Tongue N0 Yes
AB045 Gingiva N0 No
AB048 Tongue N0 Yes
AB049 Tongue N0 No
AB051 Tongue N+ Yes
AB054 Buccal Mucosa N+ Yes
AB055 Floor of Mouth N0 Yes
AB056 Retromolar Region N+ Yes
AB059 Tongue N+ Yes
AB060 Tongue, Floor of Mouth N+ Yes
AB061 Buccal Mucosa N0 Yes
AB062 Gingiva N0 No
AB063 Tongue N0 Yes
AB064 Buccal Mucosa N0 Yes
AB066 Tongue N0 Yes
AB067 Floor of Mouth N0 Yes
AB068 Gingiva N0 No
AB070 Floor of Mouth N0 Yes
AB071 Hard Palate N0 Yes
AB073 Gingiva N+ No
Table 1 Patient characteristics (Continued)
AB077 Floor of Mouth N0 Yes
AB079 Tongue N0 No
AB080 Tongue N0 No
AB081 Gingiva N+ Yes
AB082 Floor of Mouth N+ Yes
AB083 Floor of Mouth, tongue, gingiva N+ Yes
AB084 Gingiva N+ Yes
AB085 Tongue N0 Yes
AB086 Floor of Mouth N0 No
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Germantown, MD). Data were analyzed by PyroMark
Q24 2.0.6 software. The HOXA9 assay (Hs_HOXA9_
05_PM) includes three CpG islands. Methylation level
was assigned as the mean of the three sites.
RT-PCR
Total RNA was extracted from cell lines using TRIzol®
Reagent (Life Technologies, Grand Island, NY) accord-
ing to the manufacturer’s instructions. RNA quantity
was determined with a NanoDrop 2000 Spectrophotom-
eter (Thermo Fisher Scientific Inc., Asheville NC, US)
and RNA integrity was assessed with the Bioanalyzer™
(Agilent Technologies, Inc., average RIN for cell lines = 8.2).
A fixed amount of total RNA (500 ng) per each sample was
reverse transcribed with iScript™ Select cDNA Synthesis kit
(Bio-Rad, Hercules CA, US).
Standard TaqMan qRT-PCR Gene Expression assays
were conducted in triplicate to quantify HOXA9 expres-
sion levels relative to GUSB. Duplex PCR was performed
with the FAM labeled Taqman assay for HOXA9
(Hs00365956_m1) and VIC labeled Taqman assay for
GUSB (Hs00939627_m1). Reactions (10 μL per well) in-
cluded 5 μL TaqMan Gene Expression Master Mix (Life
Technologies, Grand Island, NY), 0.5 μL 20× Gene Ex-
pression Assay Mix, and 1 μL cDNA diluted to a final
concentration of 10 ng/μL. Assay plates were run on an
Applied Biosystems 7900HT detection system using
standard settings (cycling program included 2 min incu-
bation at 50°C and 10 min incubation at 95°C followed
by 40 cycles of 95°C for 15 sec and 60°C for 1 min).
Data values (Cycle Threshold [Ct] values) were extracted
from each assay with the SDS v2.0 software tool (Life
Technologies, Grand Island, NY). Gene expression values
were derived from the equation: ΔCt = (Ctgene–CtGUSB)
and expressed as 2-ΔCt.
For end point PCR, the primer sequences used to amplify
GUSB were 5’-TGCGCACAAGAGTGGTGCTGA-3′ and
5′-TCGACCCCATTCACCCACACGA-3′. The primers
for BRCA1 have been reported previously [4]. Amplifi-








































Figure 1 Pilot study evaluating methylation of HOXA9, MT1A
and HOXA11 in 3q8pq20 and non-3q8pq20 tumors. Methylation
levels of the gene promoters are shown for individual 3q8pq20 and
non-3q8pq20 tumors (open circles). The mean level is indicated by
the red bar. Differential methylation in the two oral cancer subtypes
is evident for HOXA9.
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95°C for 15 min was followed by 45 cycles of 94°C for
30 sec, 55°C (BRCA1) or 60°C (GUSB) for 30 sec, 72°C for
30 sec and a final incubation at 72°C for 10 min. Nucleo-
tide free water was used for the negative control and
Universal Human Reference RNA (Agilent technologies,
Santa Clara, CA) was used for the positive control.
Establishment of the SCC4 cell line with the HOXA9
inducible-expression construct
To generate stable, inducible cell lines expressing HOXA9
upon doxycycline induction, HOXA9 cDNA (BC10023,
Open Biosystems) was subcloned into pLVX-tight-puro
(Clontech, CA). SCC4 cells were transfected with pLVX-
Tet-On and pLVX-HOXA9 using Lipofectamine LTX
(Life Technologies, Grand Island, NY)) according to the
manufacturer’s instructions. Three days after transfection,
stable clones were selected by culturing for 2 weeks in
medium supplemented with 1 μg/mL Puromycin (Sigma-
Aldrich) and 300 μg/mL G418 (Roche). These SCC4-
HOXA9 cells were cultured with 1 μg/mL doxycycline to
induce HOXA9 expression, which was verified by qPCR
and western blotting. Empty vector control SCC4 cells
(SCC4-empty vector) were generated by transfecting with
pLVX-Tet-On and pLVX-tight-puro and selection by cul-
turing for 2 weeks in medium supplemented with 1 μg/mL
puromycin and 300 μg/mL G418.
Proliferation and colony formation assays
To assess cell proliferation, 500 SCC4-HOXA9 and SCC4-
empty vector cells were seeded in 96-well culture plates.
After allowing cells to attach and grow for 24 hours,
100 μL of culture medium supplemented with 1 μg/mL
doxycycline was added to the cultures. Plates containing
six replicate wells of each cell type were harvested over a
period of nine days and proliferation was measured using
the CyQUANT® NF assay (Life Technologies, Grand
Island, NY).
Colony formation assays were performed by seeding
cells in six-well plates at a density of 1000 cells/well in
2 mL complete medium. After culturing for two weeks,
colonies were stained with 0.5% crystal violet in 2% etha-
nol and colonies were counted.
Statistical analysis
A Wilcoxon rank sum test was used to assess differential
methylation between groups. A T-test was used to assess
differences in proliferation and colony formation assays.
Results
Pilot study evaluating methylation status of HOXA9,
HOXA11 and MT1A
Methylation and tumor genome copy number data re-
ported by Poage and colleagues [2] were accessioned andcases assigned to the 3q8pq20 or non-3q8pq20 subtypes
as described previously [1]. Information on nodal status
was not available for these cases. Methylation levels were
compared between tumor subtypes, and this analysis re-
vealed 15 loci that were differentially methylated between
3q8pq20 and non-3q8pq20 plus normal tissue (Additional
file 2: Figure S1, Additional file 1: Table S1). HOXA9,
HOXA11 and MT1A were selected for further study, be-
cause promoters of these genes were consistently highly
methylated in 3q8pq20 cases. Methylation status of the
CpG islands in these promoters was evaluated by pyrose-
quencing in 12 tumors (six 3q8pq20 and six non-3q8pq20
subtypes) from the previously reported SCC cohort#2
for which copy number and clinical follow up data were
available [1]. In this pilot study, only HOXA9 appeared
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p = 0.014 p = 0.024
Figure 2 Methylation of HOXA9 in oral cancers and cell lines. Shown are the mean and standard deviation.
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http://www.biomedcentral.com/1471-2407/14/353Association of HOXA9 methylation with risk for metastasis
The methylation status of HOXA9 was further investi-
gated in cell lines and 40 additional tumors from SCC
cohort#2 [1] by pyrosequencing (Figure 2, Additional

































































   




















Figure 3 HOXA9 is methylated and expressed at low levels in oral can
determined by pyrosequencing. b. Transcript levels determined by quantitamethylated in oral cancer cell lines and to a slightly lesser
extent in DOX, a cell line derived from dysplastic tissue
(Figure 3a). By contrast, only 30% methylation of HOXA9
was observed in the non-tumorigenic HaCaT cells. The













































cer cell lines. a. Methylation levels (mean and standard deviation) as
tive RT-PCR
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of 3q8pq20 tumors (45%) or clinically normal epithelium
from four cancer patients (16%). We also observed a sig-
nificant difference in methylation when comparing node
positive (49%) and node negative cases (38%), irrespective
of genomic subtype.
Re-expression of HOXA9 inhibits growth
In oral cancer cell lines with nearly complete methyla-
tion of the HOXA9 promoter, HOXA9 expression levels
are low (Figure 3). By contrast, HOXA9 expression levels














































Figure 4 Re-expression of HOXA9 represses proliferation and colony f
SCC4-HOXA9 and SCC4-empty vector cells. b. Colony formation by SCC4-H
BRCA1 expression.of the promoter (Figure 3). These observations suggest that
promoter methylation is frequently a mechanism whereby
expression of HOXA9 expression can be repressed in oral
cancer and pre-cancer cells.
To investigate the possible functional significance of
reduced expression of HOXA9, we re-expressed HOXA9
in SCC4 tongue cancer cells (SCC4-HOXA9), which re-
sulted in diminished proliferation compared to control
SCC4 cells with an empty vector construct (SCC4-empty
vector, Figure 4a). We also observed that fewer (p = 0.04),
and smaller colonies were formed by SCC4-HOXA9 cells









ormation and induces expression of BRCA1. a. Proliferation of
OXA9 and SCC4-empty vector cells. c. Endpoint PCR analysis of
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Figure S2). In breast cancer cells, HOXA9 has been shown
to directly regulate BRCA1 expression and to sup-
press growth and survival [4]. Expression of HOXA9
in SCC4 cells also resulted in increased expression of
BRCA1 (Figure 4c), suggesting that, in addition to pro-
moting growth, reduced expression of HOXA9 may con-
tribute to tumor genome instability.
Discussion
The risk of metastasis in oral cancer patients is associ-
ated with the status of copy number alterations at
chromosome 3q, 8p, 8q and 20. The presence of any one
of these aberrations (3q8pq20 genomic subtype) is asso-
ciated with a substantial risk of metastasis (46%), while
absence of alterations in all of these regions (non-
3q8pq20 subtype) shows greater promise as a biomarker
for low risk of metastasis (93% NPV). If validated in fur-
ther larger clinical studies, determination of non-3q8pq20
status prior to surgery could identify those patients at low
risk of metastasis who could be spared the extra surgery
of an elective neck dissection. While non-3q8pq20 status
could be determined prior to surgery by profiling tumor
biopsies for copy number alterations, assignment of non-
3q8pq20 status might be ambiguous if no copy number
changes were present on other chromosome arms.
Therefore, we investigated whether differential methy-
lation of loci could act as a surrogate and identify
3q8pq20 and non-3q8pq20 subtypes. Two of the candidate
loci (HOXA11 and MT1A), selected from analysis of pub-
lished data, failed to validate in our cohort. Only HOXA9
was found to be differentially methylated in 3q8pq20 com-
pared to non-3q8pq20 tumors, as well as between node
positive and node negative cases. Although the differences
in methylation level reached statistical significance, they
are modest and would probably not result in a robust clin-
ical test for nodal status.
Homeobox (HOX) genes are transcription factors with
roles in development, regulating patterning during em-
bryogenesis and maintaining differentiated states. De-
regulated expression of HOX genes is reported in cancers
[5]. They can be overexpressed and act as oncogenes or
they can act as tumor suppressors with expression down
regulated via promoter methylation. Our data are consist-
ent with HOXA9 acting as a tumor suppressor in oral
cancer. Methylation of HOXA9 has been reported previ-
ously in oral cavity cancer [6], and methylation and loss of
expression of HOXA9 reported in breast [4,7,8], lung [9],
ovarian [10] and bladder cancer [11], whereas HOXA9 is
well known to act as an oncogene in leukemia [5]. The
tumor suppressor function of HOXA9 has been exten-
sively investigated in breast cancer where it has been
shown that HOXA9 directly regulates BRCA1 [4] and a
number of other genes involved in invasion, growth andmetastasis [7]. While we show here that HOXA9 also
appears to positively regulate BRCA1 expression in oral
cancer cells, further studies will be required to fully under-
stand how HOXA9 functions as a tumor suppressor in
oral cancer. Indeed, the oncogenic and tumor suppressive
activities of deregulated HOXA9 expression in different
tissues highlight the importance of tissue context for the
functioning of deregulated developmental genes in cancer.
Conclusions
The HOXA9 promoter is frequently methylated in oral SCC
and diminished expression of HOXA9 confers a growth
advantage to oral SCC cells. Higher levels of HOXA9
methylation are present in tumors with greater risk of
metastasis.
Additional files
Additional file 1: Table S1. Comparison of methylation levels in
3q8pq20 cancers vs. non-3q8pq20 cancers + normals (data from NCBI
GEO, GSE20939 and GSE20742). Table S2. Methylation status of HOXA9 in
oral cancers.
Additional file 2: Figure S1. Differentially methylated loci. Copy
number and methylation data from Poage et al. [1] were obtained from
NCBI GEO (Accession numbers GSE20742 and GSE20939, respectively).
Copy number data were segmented and samples were assigned to the
3q8pq20 or non-3q8pq20 subtype based on the presence of copy
number changes, +3q, −8p, +8q, and/or +20 as described previously [2].
A nonlinear transformation was applied to the methylation data beta
values [s = sqrt(beta) - sqrt(1 - beta)], which increases the Gaussian
character of the data and has the effect of reducing the number of false
positives. The transformed data were then quantile normalized across
samples. Probes were tested for differential methylation between
3q8pq20 and non-3q8pq20 subtypes plus normal cases using the limma
package. The probes for each comparison were filtered on absolute mean
difference in methylation level (> 0.05) and adjusted p-value (< 0.05, FDR)
[3]. This analysis yielded 15 probes differentially methylated between
3q8pq20 and non-3q8pq20 samples. Figure S2. Colony formation by
SCC4 cells expressing HOXA9 and control SCC4 cells. Shown are images
of six-well plates following staining with crystal violet. SCC4-HOXA9 and
SCC4-empty vector cells were cultured in the presence of 1 μg/mL
doxycycline. Smaller colonies are present in the plates of SCC4-HOXA9
cells in which HOXA9 was re-expressed (top two panels) compared to SCC4
cells with an empty vector (SCC4-empty vector, bottom two panels).
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